Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials

Related Keywords

United States ,American ,Christi Waarich ,Andrew Robbins ,Exchange Commission ,Cogent Biosciences Inc ,American Academy Of Asthma ,Redmile Group ,Piper Sandler Co ,Jp Morgan Securities ,Cogent Research Team ,Nasdaq ,Cogent Biosciences ,Commodore Capital ,Fairmount Funds ,Adage Capital Partners ,Venrock Healthcare Capital Partners ,Piper Sandler ,Chief Executive Officer ,Nonadvanced Systemic Mastocytosis ,American Academy ,Preferred Stock ,Seriesb Preferred Stock ,Securities Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Region ,